Abstract
In the last decades, emerging molecular targets for ischemic neuroprotection and regeneration have been postulated. This fact allowed that classical drugs with well established therapeutic applications might be used in cerebrovascular diseases as well as neurodegenerative diseases. Minocycline is a commonly used antibiotic of the tetracycline family (7-dimethylamino-6-dimethyl-6-deoxytetracycline) which reveals cytoprotective capability and potential use in treatment of different diseases. Here, we discuss the literature concerning minocycline. The available data indicate that the antibiotic has multi-faceted effects on cell functions and, consequently, a number of clinical properties that are useful and/or could be useful for treatment of different diseases including bacterial infections, cancer, autoimmune disorders, ischemia as well as neurodegenerative and psychiatric diseases. Thus, application of minocycline as a therapeutic agent is the subject of clinical trials for various diseases. It is also evident that minocycline-mediated cytoprotection, including neuroprotection, is an important aspect of its clinical application. Here, we have reviewed the basis of the minocycline activity as well as different studies indicating that minocycline can be used as potential therapeutic agent in both cerebrovascular and neurodegenerative diseases in human.
Keywords: Cell death pathways, minocycline, cytoprotection, mitochondria, energy coupling, VDAC
Current Drug Targets
Title:Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases
Volume: 14 Issue: 1
Author(s): Andonis Karachitos, Julian Solis Garcia del Pozo, Piet W.J. de Groot, Hanna Kmita and Joaquin Jordan
Affiliation:
Keywords: Cell death pathways, minocycline, cytoprotection, mitochondria, energy coupling, VDAC
Abstract: In the last decades, emerging molecular targets for ischemic neuroprotection and regeneration have been postulated. This fact allowed that classical drugs with well established therapeutic applications might be used in cerebrovascular diseases as well as neurodegenerative diseases. Minocycline is a commonly used antibiotic of the tetracycline family (7-dimethylamino-6-dimethyl-6-deoxytetracycline) which reveals cytoprotective capability and potential use in treatment of different diseases. Here, we discuss the literature concerning minocycline. The available data indicate that the antibiotic has multi-faceted effects on cell functions and, consequently, a number of clinical properties that are useful and/or could be useful for treatment of different diseases including bacterial infections, cancer, autoimmune disorders, ischemia as well as neurodegenerative and psychiatric diseases. Thus, application of minocycline as a therapeutic agent is the subject of clinical trials for various diseases. It is also evident that minocycline-mediated cytoprotection, including neuroprotection, is an important aspect of its clinical application. Here, we have reviewed the basis of the minocycline activity as well as different studies indicating that minocycline can be used as potential therapeutic agent in both cerebrovascular and neurodegenerative diseases in human.
Export Options
About this article
Cite this article as:
Karachitos Andonis, Solis Garcia del Pozo Julian, W.J. de Groot Piet, Kmita Hanna and Jordan Joaquin, Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases, Current Drug Targets 2013; 14 (1) . https://dx.doi.org/10.2174/1389450111314010006
DOI https://dx.doi.org/10.2174/1389450111314010006 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology The Need for an Interdisciplinary Network of Investigations on HHT
Current Pharmaceutical Design BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Emerging Role of Bone Morphogenetic Proteins as a Context Dependent Pro-Angiogenic Cue
Current Angiogenesis (Discontinued) Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Prophylactic Neuroprotection
Current Drug Targets Non-Surgical Treatment Options for Symptomatic Uterine Leiomyomas
Current Women`s Health Reviews Cerebrospinal Fluid Flow Dynamics in Multiple Sclerosis Patients through Phase Contrast Magnetic Resonance Imaging
Current Neurovascular Research Neurological Disorders in Pregnancy
Current Women`s Health Reviews Hereditary Haemorrhagic Telangiectasia: A Rare Disease As A Model for the Study of Human Atherosclerosis
Current Pharmaceutical Design The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Vasculogenesis: Making Pipes for the Cardiovascular Plumbing
Current Angiogenesis (Discontinued) A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and Molecular Aspects
Current Pharmaceutical Design